Track market-moving stories before they get noisy

TLDR: Uniswap price fell more than 30% from its $10.90 peak as exchange inflows raised distribution concerns. Binance recorded daily UNI inflows above $40 million in late September, according to Darkfost. UNI’s $6.75-$7.00 support zone could underpin a double bottom if buyers defend it. A breakout above $7.60-$7.80 could open a path toward $8.80, according to Crypto With Gopal. Uniswap’s UNI token is showing mixed signals as heavy exchange inflows meet a potential bullish reversal pattern. The token has fallen more than 30% from its recent $10.90 peak, while Binance inflows reached their highest levels of the year.

Analyst Darkfost reported daily UNI inflows above $40 million in late September, with the inflow Z-score exceeding 4 several times. Meanwhile, Crypto With Gopal identified a potential double bottom around the 6.75–7.00 support zone.

CoinMarketCap data put UNI at $7.31, down 2.30% over 24 hours, as traders watched resistance near $7.60-$7.80.

Why UNI Exchange Inflows Matter for Uniswap Price Darkfost reported that UNI’s strong performance earlier this year coincided with improving activity across Uniswap’s decentralized exchange ecosystem. 

Uniswap’s total value locked (TVL) exceeded $4 billion in September, reaching a yearly record. Decentralized exchange trading volumes also peaked at $93.6 billion.

🗞️ UNI Inflows hit Yearly highs as distribution weighs on price

Since the start of the year, some altcoins have posted strong performances, such as UNI, the token of the DeFi platform Uniswap.

Its TVL also hit a yearly record in September, at over $4B, as did DEX volumes, which… pic.twitter.com/SBdYToPmHx

— Darkfost (@Darkfost_Coc) October 17, 2026

These fundamentals accompanied a sharp UNI rally, with gains reaching 370% from the June low. However, rising exchange inflows have since introduced selling pressure, according to Darkfost.

Exchange inflows measure tokens transferred to centralized trading platforms. Traders may deposit assets to sell them, trade derivatives, or reposition their portfolios. Therefore, inflows alone do not confirm that holders intend to sell.

Darkfost highlighted unusually elevated Binance inflows in late September. 

A Z-score above 4 indicates an exceptionally high reading relative to the metric’s historical average and variability. Daily inflows exceeding $40 million reinforced the scale of those movements.

The analyst also observed that inflow momentum appeared to be fading. If that decline continues, selling pressure could ease and help UNI establish a price bottom. 

However, a sustained reduction in inflows has not yet confirmed that distribution has ended.

UNI Price Analysis: Can Buyers Defend the $7 Support Zone? UNI’s four-hour chart shows a potential double bottom, according to Crypto With Gopal. The pattern suggests buyers are defending the $6.75-$7.00 area, although confirmation remains necessary.

A double bottom forms when price tests similar lows twice and subsequently rebounds. 

The pattern becomes more convincing if the price breaks resistance between the two lows. For UNI, the key breakout zone sits between $7.60 and $7.80.

$UNI is printing a potential double bottom formation 👀📈

Buyers are defending the $6.75–$7.00 support zone, hinting at a possible reversal. A breakout above $7.60–$7.80 could open the door toward $8.80 as bullish momentum builds 🔥

Bulls are slowly regaining strength, but a… pic.twitter.com/mllzUdxaAM

— Crypto With Gopal (@cryptowithgopal) October 17, 2026

Crypto With Gopal identified $8.80 as a potential upside target following a confirmed breakout. However, failure to clear resistance could leave UNI vulnerable to renewed selling pressure.

CoinMarketCap data showed UNI trading near $7.31, with $7.19 identified as immediate Fibonacci support. A hold above that level could support a rebound toward $7.37. 

A breakdown could expose the $7.10 swing low, while broader market weakness remains a risk.

The October 19 CME futures launch is another event traders are watching. Its actual effect on UNI will depend on market conditions and the response from participants.

For now, UNI faces two competing signals: fading exchange inflows could ease distribution, while technical support offers a potential reversal point. Traders need confirmation from both price action and inflow trends before concluding that selling pressure has subsided.

Jupiter’s [JUP] new trading product, YOLO, recorded over $1 billion in volume after its 15h October beta launch. Jupiter’s trading product on Solana offers 1,000x leverage on SOL, BTC, and ETH, and allows trading with as little as $10 to “make it big.”

Traders should remember that at that kind of leverage, a 0.1% price move against their direction could wipe out their position. As a simulated trading model, a single house pool funded by losers pays the winners, and the individual trades don’t make it to a real market, but of course the profits and losses are real.

Winners are paid when the platform’s liquidity pool can cover the entire amount, and there are no earlier claims in the queue.

The impact on JUP price trends Source: JUP/USDT on TradingView Jupiter’s long-term trend has been bullish since the swing structure break on the daily timeframe in May. The low made at $0.144 was the anchor point for the rally that pushed upwards to $0.388.

Since making this high earlier in October, Jupiter token’s price has declined by 21.8% so far.

The next long-term demand zone to watch will be at $0.22 (cyan), the bullish order block that propelled the latest JUP bullish impulse move.

Do bears have the upper hand? Source: JUP/USDT on TradingView On the 2-hour chart, the price trend shifted bearishly across the board. The demand zone at $0.32 was flipped to a supply zone too. The retest as resistance in recent days yielded a bearish reaction as well.

The next demand zone at $0.29 was already being tested at the time of writing. Given the wider market weakness due to Bitcoin’s [BTC] retracement towards $80K, it is likely that JUP would continue its descent over the next week.

A drop below $0.275 and a retest of $0.29 would likely offer short-term traders a selling opportunity.

Final Summary The 1,000x Jupiter trading product on Solana recorded over $1 billion in trading volume after its 15th October beta launch. Over the past ten days, JUP’s price has retraced by 21.8% and could slide further next week.

First Citizens Bank & Trust Co. decreased its holdings in shares of nVent Electric PLC (NYSE:NVT – Free Report) by 63.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,594 shares of the company’s stock after selling 9,905 shares during the period. First Citizens Bank & Trust Co.’s holdings in nVent Electric were worth $897,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in NVT. Sequoia Financial Advisors LLC raised its stake in shares of nVent Electric by 16.8% during the second quarter. Sequoia Financial Advisors LLC now owns 76,540 shares of the company’s stock worth $12,982,000 after purchasing an additional 11,033 shares during the last quarter. State Street Corp lifted its holdings in shares of nVent Electric by 4.9% during the second quarter. State Street Corp now owns 5,313,122 shares of the company’s stock worth $901,159,000 after purchasing an additional 250,248 shares during the period. Alua Capital Management LP acquired a new stake in shares of nVent Electric during the first quarter worth $27,394,000. Engineers Gate Manager LP grew its position in nVent Electric by 327.1% in the 2nd quarter. Engineers Gate Manager LP now owns 33,538 shares of the company’s stock valued at $5,688,000 after buying an additional 25,686 shares during the last quarter. Finally, Corient Private Wealth LP grew its position in nVent Electric by 96.0% in the 2nd quarter. Corient Private Wealth LP now owns 36,357 shares of the company’s stock valued at $6,167,000 after buying an additional 17,806 shares during the last quarter. Institutional investors and hedge funds own 90.05% of the company’s stock.

Insider Transactions at nVent Electric In related news, CEO Beth Wozniak sold 46,261 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.42, for a total value of $7,606,233.62. Following the sale, the chief executive officer directly owned 55,612 shares in the company, valued at $9,143,725.04. The trade was a 45.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Randolph A. Wacker sold 22,525 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.62, for a total transaction of $3,708,065.50. Following the completion of the sale, the chief accounting officer directly owned 27,441 shares in the company, valued at approximately $4,517,337.42. The trade was a 45.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 74,644 shares of company stock valued at $12,276,886 in the last 90 days. 1.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets A number of equities analysts have commented on the stock. Clear Str upgraded shares of nVent Electric to a “strong-buy” rating in a research report on Monday, July 13th. Zacks Research downgraded shares of nVent Electric from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. The Goldman Sachs Group reiterated a “buy” rating and set a $200.00 price target on shares of nVent Electric in a research note on Saturday, August 1st. BMO Capital Markets assumed coverage on shares of nVent Electric in a report on Sunday, October 4th. They set an “outperform” rating and a $212.00 price target for the company. Finally, Wells Fargo & Company initiated coverage on shares of nVent Electric in a report on Thursday, September 24th. They set an “equal weight” rating and a $182.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, nVent Electric has a consensus rating of “Buy” and an average price target of $200.81. Check Out Our Latest Report on NVT

nVent Electric Stock Performance NYSE:NVT opened at $142.11 on Friday. The firm’s fifty day simple moving average is $158.96 and its 200-day simple moving average is $156.24. nVent Electric PLC has a fifty-two week low of $93.22 and a fifty-two week high of $184.64. The company has a quick ratio of 1.33, a current ratio of 1.80 and a debt-to-equity ratio of 0.37. The stock has a market cap of $23.00 billion, a PE ratio of 38.83, a price-to-earnings-growth ratio of 0.79 and a beta of 1.35.

nVent Electric (NYSE:NVT – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.16 by $0.29. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.26 billion. nVent Electric had a return on equity of 18.85% and a net margin of 12.38%. The company’s quarterly revenue was up 52.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.86 EPS. nVent Electric has set its Q3 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.000-5.100 EPS. Analysts expect that nVent Electric PLC will post 5.13 earnings per share for the current fiscal year.

nVent Electric Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 23rd will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, October 23rd. nVent Electric’s payout ratio is 22.95%.

About nVent Electric (Free Report)

nVent Electric plc is a global provider of electrical connection and protection solutions. The company designs and manufactures products that help protect, connect and manage electrical, electronic and critical infrastructure systems in industrial, commercial, data center, energy, transportation and other applications.

Its portfolio includes electrical and electronic enclosures, cable management systems, fastening and support products, grounding and bonding solutions, busbar and power distribution equipment, surge protection products, and thermal management systems.

Featured Stories Five stocks we like better than nVent Electric Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding NVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for nVent Electric PLC (NYSE:NVT – Free Report).

Receive News & Ratings for nVent Electric Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for nVent Electric and related companies with MarketBeat.com's FREE daily email newsletter.

Covington Investment Advisors Inc. boosted its position in shares of NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 163,112 shares of the computer hardware maker’s stock after purchasing an additional 3,413 shares during the quarter. NVIDIA makes up 4.2% of Covington Investment Advisors Inc.’s portfolio, making the stock its 4th biggest holding. Covington Investment Advisors Inc.’s holdings in NVIDIA were worth $32,637,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of NVDA. Jupiter Topco LLC acquired a new stake in shares of NVIDIA in the second quarter valued at approximately $16,156,076,000. Van ECK Associates Corp raised its position in shares of NVIDIA by 34.7% in the 2nd quarter. Van ECK Associates Corp now owns 75,849,721 shares of the computer hardware maker’s stock worth $15,176,771,000 after buying an additional 19,522,304 shares during the period. Amundi raised its position in shares of NVIDIA by 10.4% in the 1st quarter. Amundi now owns 133,768,018 shares of the computer hardware maker’s stock worth $23,329,141,000 after buying an additional 12,575,177 shares during the period. SEB Asset Management AB purchased a new position in shares of NVIDIA in the 1st quarter worth $1,692,807,000. Finally, Employees Provident Fund Board acquired a new position in NVIDIA in the fourth quarter valued at $1,243,336,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Key Headlines Impacting NVIDIA Here are the key news stories impacting NVIDIA this week:

Positive Sentiment: New RTX Spark laptops expand NVIDIA’s addressable market. Systems from ASUS, Dell, HP, Lenovo, Microsoft and MSI are now available starting at $2,599, combining Blackwell graphics, up to 128GB of memory and local AI capabilities. The launch could create a new consumer and developer revenue stream beyond data centers. NVIDIA RTX Spark PCs Available Today Positive Sentiment: Automotive and enterprise adoption continues. Volvo expanded its partnership with NVIDIA for automated-driving systems, while Adobe is integrating NVIDIA technology across Photoshop, Premiere and other creative tools. These agreements support longer-term demand for NVIDIA hardware and software. Volvo Cars expands automated driving partnership Positive Sentiment: Supply-chain investment and customer deployments remain strong. Taiwan is reportedly considering as much as $4 billion for Texas industrial parks serving NVIDIA suppliers, and customers continue deploying Blackwell systems. The developments reinforce demand, although they may take time to affect revenue. Taiwan Texas industrial parks Neutral Sentiment: NVIDIA is broadening its software and AI-model ecosystem. Paid offerings such as AI Enterprise and Mission Control, along with Nemotron open models and partnerships with AI startups, could make earnings less dependent on hardware. However, the articles provide no near-term financial contribution. Negative Sentiment: AI financing concerns are the main pressure. CoreWeave’s debt has reportedly traded at distressed yields, raising questions about whether highly leveraged customers can continue funding data-center expansion. Higher Treasury yields and inflation concerns are also making large AI projects more expensive. CoreWeave financing worries Negative Sentiment: Investors are questioning AI growth expectations. OpenAI’s reported $50 billion revenue run rate was below the roughly $68 billion previously anticipated, prompting concern that AI demand may mature more slowly. Microsoft’s development of custom Maia chips also highlights the risk of customers developing alternatives to NVIDIA GPUs. OpenAI revenue expectations Negative Sentiment: Reported insider selling adds a sentiment overhang. Recent data showed NVIDIA insiders made numerous sales and no open-market purchases over the past six months, though such transactions may reflect planned diversification rather than a change in business outlook. Insider Activity at NVIDIA In other news, Director Mark A. Stevens sold 622,239 shares of NVIDIA stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $231.62, for a total value of $144,122,997.18. Following the transaction, the director owned 2,336,531 shares of the company’s stock, valued at $541,187,310.22. This trade represents a 21.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy S. Teter sold 30,460 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $222.80, for a total value of $6,786,488.00. Following the completion of the transaction, the executive vice president directly owned 2,687,660 shares of the company’s stock, valued at approximately $598,810,648. This trade represents a 1.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,766,118 shares of company stock valued at $399,450,353 over the last ninety days. Insiders own 3.94% of the company’s stock. NVIDIA Stock Down 1.4% Shares of NVIDIA stock opened at $214.13 on Friday. The company has a quick ratio of 3.85, a current ratio of 4.59 and a debt-to-equity ratio of 0.14. NVIDIA Corporation has a fifty-two week low of $164.27 and a fifty-two week high of $243.37. The business has a 50-day moving average price of $223.20 and a 200 day moving average price of $211.10. The firm has a market cap of $5.16 trillion, a P/E ratio of 31.48, a P/E/G ratio of 1.67 and a beta of 2.22.

NVIDIA (NASDAQ:NVDA – Get Free Report) last released its quarterly earnings data on Wednesday, August 26th. The computer hardware maker reported $2.22 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. The business had revenue of $96.22 billion for the quarter, compared to analysts’ expectations of $92.27 billion. NVIDIA had a net margin of 63.66% and a return on equity of 96.04%. The company’s revenue for the quarter was up 105.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 EPS. On average, sell-side analysts forecast that NVIDIA Corporation will post 9.27 earnings per share for the current fiscal year.

NVIDIA declared that its board has approved a stock repurchase plan on Monday, September 28th that permits the company to buy back $150.00 billion in outstanding shares. This repurchase authorization permits the computer hardware maker to purchase up to 2.8% of its shares through open market purchases. Share repurchase plans are often a sign that the company’s leadership believes its shares are undervalued.

NVIDIA Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Thursday, September 10th were given a $0.25 dividend. The ex-dividend date was Thursday, September 10th. This represents a $1.00 annualized dividend and a yield of 0.5%. NVIDIA’s payout ratio is 12.64%.

Wall Street Analyst Weigh In A number of equities research analysts have issued reports on the company. China Renaissance boosted their price target on NVIDIA from $319.00 to $330.00 and gave the company a “buy” rating in a research report on Monday, August 31st. HSBC raised their price objective on NVIDIA from $360.00 to $365.00 in a report on Thursday, August 27th. Rothschild & Co Redburn raised their price objective on NVIDIA from $300.00 to $325.00 in a report on Thursday, August 27th. Phillip Securities lifted their price objective on NVIDIA from $285.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Finally, Rosenblatt Securities reiterated a “buy” rating and set a $390.00 target price on shares of NVIDIA in a report on Tuesday, September 29th. Five investment analysts have rated the stock with a Strong Buy rating, forty-nine have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, NVIDIA currently has a consensus rating of “Buy” and a consensus target price of $321.89.

Read Our Latest Research Report on NVIDIA

NVIDIA Profile (Free Report)

NVIDIA Corporation is a technology company that designs accelerated computing platforms, graphics processing units (GPUs), central processing units (CPUs), networking products and related software. Its technologies are used in artificial intelligence, data centers, scientific and technical computing, gaming, professional visualization, automotive systems and robotics.

The company’s products include GeForce GPUs and gaming software, data center computing platforms, networking solutions, and enterprise software for AI development and deployment.

Featured Stories Five stocks we like better than NVIDIA Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding NVDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Corporation (NASDAQ:NVDA – Free Report).

Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.

The "Magnificent Seven" stocks have powered the S&P 500 higher over the past several years, thanks to their leadership in the technology space and, in many cases, their prominence in the high-potential area of artificial intelligence (AI). These companies operate across a range of specialty areas, from smartphones to social media, and each dominates its field -- and has established a strong track record of revenue growth over time.

You would expect such stocks to be particularly expensive after their gains in recent years. But that isn't the case. In fact, one stands out as a once-in-a-decade buying opportunity, as the cheapest of the "Magnificent Seven," and it's also close to its own valuation low. This AI stock has soared more than 900% over the past five years and is well-positioned for further gains as the AI story continues to unfold. Let's check out this surprisingly cheap stock to buy now, before the price goes up.

Image source: Getty Images.

Seven well-known tech giantsSo, first, let's take a quick look at the "Magnificent Seven." Most of us are probably familiar with these names, as they have built their reputations and businesses over time, and in most cases, their products are in the public eye. These companies are: Apple, Amazon, Alphabet, Meta Platforms, Microsoft, Nvidia (NVDA -1.43%), and Tesla.

Investors have rushed to get in on these stocks in recent years to bet on the AI story and technology in general. At times, valuations reached high levels, but today, many of them, in spite of the positive stock performance, are trading at reasonable prices. This is as earnings have also taken off.

And the best bargain of the bunch just so happens to be the biggest AI winner of all, at least so far, and that's Nvidia. The company trades for 23x forward earnings estimates, making it even cheaper than Meta, a stock that's been among the cheapest of the "Magnificent Seven" in recent years.

META PE Ratio (Forward) data by YCharts

Now, here's why I think such levels won't last and that this is a once-in-a-decade buying opportunity. We'll start by talking about the business Nvidia has built. The company is known for its graphics processing units (GPUs), the chips needed for essential AI tasks like the training of models. The GPU and Nvidia's related products and services have generated enormous earnings growth, with revenue and profit each climbing in the double and triple digits quarter after quarter. In the latest period, they reached $96 billion and $59 billion, respectively.

Why customers like the fastest GPUsCustomers rush to Nvidia because its GPUs are the fastest, and this is a major plus -- speed equals efficiency and over time may lower costs. Nvidia has expanded its repertoire as the AI boom has evolved, positioning itself to win in the upcoming phases of growth, and, with this in mind, it recently made a key move.

NVDA Nvidia$214.13-$3.10 (-1.43%)

NASDAQ · As of 4:00 PM ET 10/16/26

Nvidia has entered the stand-alone central processing unit (CPU) market as CPUs are seen as the key chips powering agentic AI. This involves AI handling real problems and taking multi-step actions, and it's viewed as a big growth driver in the coming years. Nvidia says the stand-alone CPU market is worth $200 billion, and the company aims to become a leader.

So, Nvidia's explosive growth in the early stages of the AI boom may not be the end of the story. The company could be heading for another big wave of growth as agentic AI use gathers momentum. Nvidia is in the process of rolling out its first CPUs and expects $20 billion in revenue from them this year alone. This offers us reason to be optimistic about what's ahead.

While Nvidia's explosive growth may keep its valuation somewhat in check, I still see today's level as exceptionally cheap -- and possibly a once-in-a-decade opportunity for growth investors looking for a long-term AI victory.

By You're currently following this author! Click to unsubscribe from email alerts.

Walmart is expecting up to an additional percentage point of inflation due to fuel costs in 2027, according to Deutsche Bank. David Paul Morris/Bloomberg via Getty Images Just when US shoppers might have thought they dodged the tariff jab, energy costs are coming in with the right hook.

Deutsche Bank says Walmart executives are now expecting the added cost of higher diesel prices to wipe out their total expected benefit from tariff refunds and push prices back up, according to a Thursday analyst note following a meeting with Walmart CFO John David Rainey.

"Elevated diesel is pressuring WMT directly through transportation costs and indirectly as suppliers pass through higher costs, including on petroleum-linked products," the analysts wrote. "Elevated diesel costs are beginning to flow through to consumer prices"

The company is now expecting an additional half to one percentage point of inflation in 2027, the note said. At that rate, additional fuel costs this year and next year will completely erase Walmart's $2.9 billion tariff refund.

Walmart said in August that it had been putting the bulk of that tariff refund money toward lower prices for shoppers.

"Like other retailers, we are not immune to sustained increases in fuel and transportation costs, but we work to minimize their impact," a spokesperson told Business Insider.

The spokesperson also said that many of Walmart's current discounts and holiday deals are time-bound, after which some prices may return to regular levels.

"That should not be characterized as a broad-based price increase," the spokesperson said.

Beyond Walmart, which runs one of the most efficient supply chains in all of retail, the energy impact could be even more pronounced.

The Deutsche Bank analysts noted that competing retailers are also hiking prices in similar categories, leaving Walmart with the relative low-price advantage. The bank also upgraded its rating of Walmart's stock.

Read next

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Dominick Reuter You're currently following this author! Click to unsubscribe from email alerts.

Dominick Reuter is a senior retail reporter for Business Insider, primarily covering Walmart, Target, Costco, and other big box retailers. His stories tend to focus on issues and trends that affect employees and customers, such as affordability challenges and the growing race to provide ultra-fast delivery services on e-commerce orders.Prior to joining BI in 2019, Dominick worked for more than a decade as an independent photojournalist covering a wide range of stories for global wire services and newspapers, including Reuters, the Wall Street Journal, and Agence France-Presse.Dominick studied photojournalism at Boston University and later earned a Masters in business and economics journalism from Columbia University.If you're an employee or customer with a story to share, please contact me via email or text/call/Signal at 646-768-4750.

Walmart

Banque Pictet & Cie SA boosted its stake in shares of PepsiCo, Inc. (NASDAQ:PEP – Free Report) by 14.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,844 shares of the company’s stock after buying an additional 21,663 shares during the quarter. Banque Pictet & Cie SA’s holdings in PepsiCo were worth $22,156,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PEP. Rise Advisors LLC grew its holdings in PepsiCo by 17.1% during the 3rd quarter. Rise Advisors LLC now owns 1,852 shares of the company’s stock valued at $235,000 after buying an additional 271 shares in the last quarter. James T. Borello RIA purchased a new stake in shares of PepsiCo in the third quarter worth about $131,000. V Square Quantitative Management LLC lifted its holdings in shares of PepsiCo by 4.1% in the third quarter. V Square Quantitative Management LLC now owns 31,761 shares of the company’s stock worth $4,025,000 after buying an additional 1,265 shares in the last quarter. YANKCOM Partnership boosted its position in shares of PepsiCo by 9.2% in the third quarter. YANKCOM Partnership now owns 11,260 shares of the company’s stock valued at $1,427,000 after acquiring an additional 945 shares during the period. Finally, Financial & Tax Architects LLC grew its stake in PepsiCo by 7.4% during the third quarter. Financial & Tax Architects LLC now owns 52,098 shares of the company’s stock valued at $6,602,000 after acquiring an additional 3,589 shares in the last quarter. Institutional investors own 73.07% of the company’s stock.

Insider Buying and Selling at PepsiCo In other news, Director Robert Pohlad acquired 184,646 shares of PepsiCo stock in a transaction that occurred on Wednesday, October 14th. The shares were bought at an average cost of $128.28 per share, with a total value of $23,686,388.88. Following the transaction, the director directly owned 433,009 shares of the company’s stock, valued at $55,546,394.52. This trade represents a 74.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Flavell sold 2,900 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $139.54, for a total transaction of $404,666.00. Following the completion of the sale, the executive vice president directly owned 74,825 shares of the company’s stock, valued at approximately $10,441,080.50. The trade was a 3.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth PEP has been the topic of several analyst reports. JPMorgan Chase & Co. decreased their price objective on PepsiCo from $138.00 to $137.00 and set a “neutral” rating on the stock in a report on Friday, October 9th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $132.00 target price on shares of PepsiCo in a report on Friday, October 9th. Weiss Ratings lowered PepsiCo from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, September 24th. UBS Group decreased their price target on PepsiCo from $159.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, October 2nd. Finally, Piper Sandler lowered their price objective on PepsiCo from $176.00 to $140.00 and set an “overweight” rating for the company in a research report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $145.50. Read Our Latest Stock Report on PEP

PepsiCo Stock Performance Shares of NASDAQ PEP opened at $131.49 on Friday. The firm’s 50-day moving average price is $134.44 and its 200-day moving average price is $142.25. The company has a quick ratio of 0.76, a current ratio of 0.94 and a debt-to-equity ratio of 1.90. The company has a market cap of $179.19 billion, a PE ratio of 15.27, a PEG ratio of 3.82 and a beta of 0.35. PepsiCo, Inc. has a 52-week low of $123.47 and a 52-week high of $171.48.

PepsiCo (NASDAQ:PEP – Get Free Report) last issued its quarterly earnings results on Wednesday, October 7th. The company reported $2.34 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.05. The business had revenue of $25.27 billion during the quarter, compared to analysts’ expectations of $24.95 billion. PepsiCo had a return on equity of 53.08% and a net margin of 11.09%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 earnings per share. As a group, analysts anticipate that PepsiCo, Inc. will post 8.41 EPS for the current year.

Key Headlines Impacting PepsiCo Here are the key news stories impacting PepsiCo this week:

Positive Sentiment: Director Robert Pohlad bought 184,646 shares for approximately $23.7 million, increasing his direct ownership by 74.35%. The purchase may signal confidence that PepsiCo’s depressed valuation does not reflect its long-term prospects. SEC insider transaction filing Positive Sentiment: Bank of America maintained a Hold rating but raised its price target to $145, suggesting balanced risk-reward and potential upside from current levels. The firm cited strength at Taco Bell as partially offsetting the KFC loss. Bank of America rating update Neutral Sentiment: PepsiCo announced a €500 million offering of 3.750% senior notes. The proceeds strengthen funding flexibility, although the transaction adds to the company’s already elevated debt burden. PepsiCo euro-denominated senior notes announcement Neutral Sentiment: PepsiCo, its foundation and Feed the Children reported distributing 2 million meals through a school-based hunger-relief program. The announcement supports corporate reputation but is unlikely to materially affect earnings. PepsiCo hunger-relief program announcement Negative Sentiment: KFC will replace Pepsi beverages with Coca-Cola products at U.S. restaurants beginning in January 2027, with a full rollout expected by spring. Although KFC represents a limited portion of PepsiCo’s sales, investors view the loss as a setback for its U.S. food-service business and brand presence. Reuters report on KFC switching beverage suppliers Negative Sentiment: In India, PepsiCo warned that its Sting and Adrenaline Rush energy drinks could run out within two months after a court declined to suspend restrictions on “energy drink” labeling. The dispute could cause supply disruptions and allow competitors such as Red Bull to gain share. PepsiCo India energy-drink supply report About PepsiCo (Free Report)

PepsiCo, Inc (NASDAQ:PEP) is a global food and beverage company that develops, manufactures, markets and distributes a broad portfolio of snacks, drinks and convenient foods. Its beverage brands include Pepsi, Mountain Dew, Gatorade, 7UP in select markets, and bubly, while its food and snack brands include Lay’s, Doritos, Cheetos, Tostitos, Fritos, Quaker and Ruffles.

The company’s operations include beverage production and distribution, snack foods, convenient meals and nutrition-oriented products.

See Also Five stocks we like better than PepsiCo Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding PEP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PepsiCo, Inc. (NASDAQ:PEP – Free Report).

Receive News & Ratings for PepsiCo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepsiCo and related companies with MarketBeat.com's FREE daily email newsletter.

Annex Advisory Services LLC boosted its position in shares of Deere & Company (NYSE:DE – Free Report) by 1.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,109 shares of the industrial products company’s stock after buying an additional 890 shares during the period. Annex Advisory Services LLC’s holdings in Deere & Company were worth $39,694,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Deere & Company in the 2nd quarter valued at about $11,763,504,000. Wellington Management Group LLP increased its stake in Deere & Company by 84.3% during the second quarter. Wellington Management Group LLP now owns 3,088,628 shares of the industrial products company’s stock worth $1,959,209,000 after acquiring an additional 1,412,694 shares during the last quarter. Bank of America Corp DE bought a new stake in Deere & Company during the second quarter worth approximately $1,685,093,000. Bank of New York Mellon Corp bought a new stake in shares of Deere & Company in the 2nd quarter valued at approximately $1,259,279,000. Finally, Legal & General Group Plc bought a new stake in shares of Deere & Company in the 2nd quarter valued at approximately $957,456,000. Hedge funds and other institutional investors own 68.58% of the company’s stock.

Deere & Company Price Performance Shares of DE stock opened at $641.46 on Friday. Deere & Company has a twelve month low of $454.50 and a twelve month high of $721.22. The company has a current ratio of 2.10, a quick ratio of 1.89 and a debt-to-equity ratio of 1.45. The stock has a fifty day simple moving average of $658.05 and a two-hundred day simple moving average of $611.83. The stock has a market capitalization of $172.95 billion, a price-to-earnings ratio of 36.15, a P/E/G ratio of 2.38 and a beta of 0.86.

Deere & Company (NYSE:DE – Get Free Report) last announced its quarterly earnings results on Thursday, August 20th. The industrial products company reported $5.10 EPS for the quarter, beating the consensus estimate of $4.69 by $0.41. Deere & Company had a return on equity of 18.10% and a net margin of 10.16%. The firm had revenue of $12.61 billion for the quarter, compared to analyst estimates of $10.81 billion. During the same quarter last year, the firm posted $4.75 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, analysts predict that Deere & Company will post 18.11 EPS for the current fiscal year. Deere & Company Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Monday, November 9th. Stockholders of record on Wednesday, September 30th will be issued a $1.62 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $6.48 annualized dividend and a dividend yield of 1.0%. Deere & Company’s payout ratio is currently 36.00%.

Analysts Set New Price Targets Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Deere & Company from $585.00 to $625.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Weiss Ratings upgraded shares of Deere & Company from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, September 21st. Wall Street Zen lowered shares of Deere & Company from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. DA Davidson raised their price objective on shares of Deere & Company from $685.00 to $760.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. Finally, Seaport Research Partners set a $570.00 target price on Deere & Company in a research report on Friday, August 14th. Seventeen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $688.10.

View Our Latest Stock Analysis on DE

Deere & Company Profile (Free Report)

Deere & Company, commonly known as John Deere, is a global manufacturer of agricultural, construction, forestry and turf-care equipment. The company’s products include tractors, combines, planters, sprayers, harvesting equipment, earthmoving machinery, forestry equipment, commercial and residential lawn-care products, and related technology solutions.

Deere operates through businesses serving production and precision agriculture, small agriculture and turf, and construction and forestry markets.

Further Reading Five stocks we like better than Deere & Company Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding DE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deere & Company (NYSE:DE – Free Report).

Receive News & Ratings for Deere & Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deere & Company and related companies with MarketBeat.com's FREE daily email newsletter.

Plug Power (PLUG -7.07%), a developer of hydrogen charging technologies, went public in 1999 at a reverse-split-adjusted price of $150. It reached a record high of $1,498 at the peak of the dot-com bubble in early 2020, but now trades at roughly $1 per share. Could investing $1,000 in this beaten-down stock generate life-changing gains for daring investors?

Image source: Getty Images.

What happened to Plug Power? Plug Power originally planned to build hydrogen charging systems for homes. But after those ambitious plans fizzled out, it pivoted toward hydrogen fuel cells, charging systems, electrolyzers, and storage systems. It's already deployed 76,000 fuel cell systems, but it's heavily dependent on Amazon and Walmart, both of which use its fuel cells and charging systems in their hydrogen-powered forklifts. However, most of Plug's recent growth has been driven by its sales of electrolyzers for new decarbonization projects.

$1.38-$0.11 (-7.07%)

NASDAQ · As of 4:00 PM ET 10/16/26

Plug struggled with lumpy revenue growth over the past few years as the macro headwinds disrupted hydrogen charging projects. But from 2025 to 2028, analysts expect its revenue to grow at an 18% CAGR as it narrows its net losses. That's an impressive growth trajectory for a stock that trades at less than two times next year's sales.

Plug Power could command a higher valuation and deliver multibagger gains over the next decade if it diversifies its business beyond Amazon and Walmart and successfully executes its "Project Quantum Leap" cost-cutting initiatives. However, it's still a speculative stock that could be easily delisted if it can't prove its business model is sustainable.

Leo Sun has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Walmart. The Motley Fool has a disclosure policy.

Australian Dollar Recovers Above $0.69 vs US Dollar After Jobs Shock Cuts RBA Hike Bets Crédit Agricole retains its Australian Dollar recovery forecast, arguing that weaker jobs have yet to remove the RBA's case for tackling inflation. The Australian Dollar-to-US Dollar exchange rate recovered to US$0.6942 on Friday evening, up 0.35% from Thursday's close, after September's employment slump weakened expectations for further Australian rate increases.

Latest-Exchange Rates:

Pound to Australian Dollar (GBP/AUD): 1.919204 (+0.04%)

Euro to Australian Dollar (EUR/AUD): 1.618195 (-0.16%)

Crédit Agricole has kept its end-2026 AUD/USD forecast at 0.69, close to Friday's rate, but still expects the currency to reach 0.73 by December 2027.

Its recovery case depends in part on inflation remaining persistent enough to preserve Australia's interest-rate advantage, even as the labour market weakens.

Westpac economist Luka Belobrajdic writes: "Australian government bond yields fell following weaker labour market data, with both the 3-year and 10-year yields declining 10bps."

His early-Friday report adds: "The probability of a November hike fell to just above 12%, taking the implied year-end cash rate to 4.73%."

The current cash rate is 4.60%, following September's quarter-point increase.

Reduced expectations for further rises weaken the appeal of Australian assets to investors seeking interest income.

Part-time losses account for September's jobs decline The ABS reported a 39,300 fall in employment in September.

Part-time employment fell by 73,700 while full-time employment rose by 34,400, and total hours worked increased slightly.

A drop in participation also limited the increase in unemployment, which reached 4.7%.

The release has strengthened the argument for an RBA pause, although Crédit Agricole's senior FX strategist David Forrester cautions against assuming the central bank will treat it as decisive:

"It is worth noting that the RBA has raised doubts about the labour market data, which has become even more volatile than usual due to the ABS introducing a new survey method. So, the labour market data will carry less weight than usual with the RBA leaving another rate hike on the table."

The ABS says residual effects from changes in supplementary-survey collection may still be influencing September's figures, but its quality checks found the statistics fit for use.

It recommends the trend estimates for judging underlying conditions.

Those showed employment rising by 15,700 and unemployment holding at 4.6% in September, contrasting with the seasonally adjusted jobs decline.

Over the year, however, trend unemployment was up 0.3 percentage points, while the proportion of workers wanting more hours had also increased.

Forrester writes: "The trend labour market data points to a grind higher in the unemployment rate as well as broader measures of labour market slack including the underemployment and underutilisation rates."

The RBA has already accepted a cost to employment The policy question is how much cooling the RBA considers necessary to bring inflation back under control.

Its September meeting minutes show officials willing to accept slower growth in demand and employment in response to more persistent cost pressures.

The minutes predate the latest jobs figures.

Policymakers were concerned that underlying inflation reflected greater domestic capacity constraints, with weak productivity keeping labour costs elevated even without particularly strong wage growth.

Crédit Agricole describes the resulting support for the currency:

"The AUD is clinging to its rate advantage as sticky inflation forces the RBA to continue raising rates even while other central banks join the tightening cycle, making the currency a favoured carry trade."

Forrester records the repricing after the jobs release:

"Weak labour market data has seen the Australian rates market reduce pricing for further rate hikes from another hike as a certainty with some chance of two more 25bp rate hikes by mid-2027 to pricing in only a strong chance of another 25bp rate hike by mid-2027."

UBS also projects AUD/USD at 0.73, although it reaches that level by September 2027, three months earlier than Crédit Agricole.

The next Australian inflation release on 28 October will include the September-quarter figures.

It follows August's annual headline inflation of 4.0% and trimmed-mean inflation of 3.6%, a measure that reduces the influence of unusually large price changes.

Forrester expects the RBA to resist those softer rate expectations:

"The views of RBA Deputy Governor Andrew Hauser and Assistant Governor Chris Kent on the recent labour market data will be key drivers of the AUD in the coming week. We think that both will remain hawkish pointing to inflation being the ultimate determinant of the next move in rates."

AUD/USD Exchange Rate FAQ What does Crédit Agricole forecast for AUD/USD?

It forecasts 0.69 at end-2026 and 0.73 by December 2027. UBS projects 0.73 by September 2027.

Has September's jobs report ruled out another RBA hike?

No. It weakened market expectations for further increases, but Crédit Agricole argues that inflation could still require another move.

When is Australia's next inflation release?

The ABS schedules the September release for 28 October, including September-quarter figures.

First Citizens Bank & Trust Co. trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 59.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,522 shares of the biotechnology company’s stock after selling 2,241 shares during the period. First Citizens Bank & Trust Co.’s holdings in United Therapeutics were worth $825,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Callan Family Office LLC bought a new position in United Therapeutics during the second quarter valued at approximately $1,217,000. Andra AP fonden grew its position in United Therapeutics by 33.5% in the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after acquiring an additional 8,760 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in United Therapeutics in the second quarter worth approximately $3,359,000. Partners Capital Investment Group LLP acquired a new position in shares of United Therapeutics during the 2nd quarter worth $1,691,000. Finally, Hsbc Holdings PLC increased its stake in shares of United Therapeutics by 6.6% during the 2nd quarter. Hsbc Holdings PLC now owns 127,125 shares of the biotechnology company’s stock worth $68,899,000 after purchasing an additional 7,890 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.5% Shares of United Therapeutics stock opened at $533.12 on Friday. The stock has a market capitalization of $22.87 billion, a P/E ratio of 19.07, a PEG ratio of 3.87 and a beta of 0.49. The stock has a 50 day moving average price of $513.64 and a two-hundred day moving average price of $540.40. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter last year, the company posted $6.41 earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.40 earnings per share for the current year. More United Therapeutics News Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares. Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels. Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing Analyst Ratings Changes A number of research analysts have recently weighed in on the stock. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Morgan Stanley increased their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $642.69.

View Our Latest Analysis on United Therapeutics

Insiders Place Their Bets In related news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $539.99, for a total value of $5,129,905.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $175,195,975.57. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at $24,587,119.60. This trade represents a 15.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 392,028 shares of company stock valued at $202,884,996 over the last 90 days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Profile (Free Report)

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.

See Also Five stocks we like better than United Therapeutics Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Aptos [APT] rebounded by over 13% in 24 hours as the wider market recovered. Altcoins took the lead on this recovery as the total market cap of all cryptos surpassed $2.77 trillion, up by more than 2.21%.

At the time of writing, APT’s daily trading volume was $100 million, primarily driven by the hype around the upgrade of the ecosystem. What are the final details of the update though?

Aptos Labs announces upgrade as network reacts
Aptos Labs announced the upgrade of Block-STM, which has been running in parallel on Aptos since the mainnet. This upgrade was completed on 15th October and was named Block-STM v2, with other chains building on it.

This upgrade has since increased transaction throughput and scalability. In fact, this process was explained by Aptos Labs’ Head of Research Alexander Spiegelman and Near Protocol [NEAR] co-founder Illia Polosukhin.

Source: Aptos/X
As a result, the throughput and network activity responded instantly. For instance, the chain’s TPS hit a peak value of 1,308 while the real-time throughput was 174. This revealed that there was a difference between the theoretical and real values.

Additionally, Daily Active Accounts rose from 46,670 to 49,385, a 5.82% uptick.

As a result, the monthly total of active accounts hit a peak of 710,712, with still 16 days to go before the end of October. New Accounts Created also grew from 4,098 to 4,395.

Source: Aptos Labs Explorer
User transactions also followed suit with a rise of more than 1.335 million in a single day. That is, 9.575 million transactions compared to 10.91 million the following day.

Why are bulls struggling to break resistance level?
However, on the 4-hour chart, APT’s price was rising but facing a huge blockade at $0.8777. Every time the price hit this level, it got rejected and even had a fake breakout five days ago.

At press time, APT was trading above $0.8777, with the same faintly flipping the SuperTrend indicator to bullish. Still, it wasn’t confirmation if the altcoin’s bulls can keep it out of this consolidation.

This may be why the RSI Divergence has been bearish. However, it broke above the neutral level with a reading of 62.41.

Source: APT/USDT on TradingView
Therefore, the sustained APT uptrend could face rejection at $0.9653, a level that triggered a sharp drop to $0.7620. If buyers keep charging, the altcoin may reclaim $1 now that a network upgrade is in place and is boosting activity.

Final Summary

APT rallied by over 13% after Aptos Labs announced a network upgrade to Block-STM v2. 
APT broke above the $0.8777 resistance level, with bulls now targeting $1. 

Enso, the Zurich-based execution infrastructure platform for onchain finance, has made xStocks available on Arbitrum through its API and RWA App. The integration means wallets, fintechs and trading platforms already connected to the Enso API can extend tokenized US equity access to Arbitrum without constructing new routing or aggregation infrastructure.
xStocks are tokenized representations of US-listed equities. By routing them through Enso’s existing execution layer, applications gain access alongside the same infrastructure already used for swaps, cross-chain routing and other DeFi actions across the networks Enso supports. Eligible users can also trade xStocks directly through the Enso RWA App within Arbitrum’s onchain ecosystem.

The distribution problem in tokenized assets
Connor Howe, co-founder and chief executive of Enso, identified what he sees as the core structural gap in real-world asset (RWA) markets. “Tokenization solved the supply side of real-world assets but what’s been missing is distribution, the liquidity, routing and execution to get those assets into the wallets and apps where people actually transact,” he said. “Bringing that to Arbitrum means any wallet, fintech or trading platform already built on Enso can offer tokenized equity access to one of Ethereum’s largest ecosystems without building anything new.”

The point is well-grounded in the current state of the market. Tokenized equity issuance has expanded materially over the past two years, but access has remained fragmented. Each new chain or venue has typically required application developers to build bespoke integrations, raising the cost and slowing adoption. Enso’s pitch is a single API that absorbs that complexity, a model it says is already powering ether.fi Cash’s tokenized stock and metals execution, an approved minting role for Ondo Finance, and the infrastructure behind Anchorage Digital’s Porto institutional terminal.

Peter Haymond, head of DeFi partnerships at Arbitrum, said real-world assets are one of the fastest-growing categories on the network and that execution infrastructure is what converts that growth into something developers can ship. The xStocks integration, he argued, is the kind of composability that compounds as more real-world assets move onchain.

Regulatory backdrop and market momentum
The timing sits against a broader wave of institutional interest in tokenized equities. The announcement noted that NYSE parent ICE and crypto exchange OKX filed with the US Securities and Exchange Commission this week for a 24/7 venue that would trade more than 60 tokenized US stocks. If approved, that would mark a significant step in legitimising tokenized equity infrastructure as a regulated asset class rather than a DeFi experiment.

In the EU, MiCA provides a framework for certain crypto-asset types, but tokenized securities remain subject to existing securities law, meaning any platform offering them to European users must navigate MiFID II compliance. In the UK, the Financial Conduct Authority‘s sandbox for digital securities is still developing clear rules. The regulatory path for tokenized equities therefore varies by jurisdiction, and Enso’s release does not specify which users are eligible to trade through the RWA App or which regulatory frameworks govern its institutional clients.

Enso says it has settled more than $22 billion onchain for more than 350 enterprise clients. The company is backed by Polychain Capital, Multicoin Capital, Spartan Group and Hypersphere, though no new funding was announced alongside this integration.

AI level 1 of 5: written by Darlyn Ho; AI helped with tone, structure or wording; edited and signed off by Mark Walker, Editorial Director. What the levels mean

Assenagon Asset Management S.A. grew its holdings in shares of MKS Inc. (NASDAQ:MKSI – Free Report) by 1,742.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 442,273 shares of the scientific and technical instruments company’s stock after buying an additional 418,264 shares during the period. Assenagon Asset Management S.A. owned 0.65% of MKS worth $117,362,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Loftus Peak Pty Ltd boosted its position in shares of MKS by 21.4% in the 3rd quarter. Loftus Peak Pty Ltd now owns 57,593 shares of the scientific and technical instruments company’s stock worth $15,283,000 after purchasing an additional 10,157 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new stake in shares of MKS in the third quarter worth $575,000. NorthCrest Asset Manangement LLC increased its holdings in shares of MKS by 19.5% during the third quarter. NorthCrest Asset Manangement LLC now owns 1,262 shares of the scientific and technical instruments company’s stock valued at $329,000 after acquiring an additional 206 shares in the last quarter. Wedmont Private Capital increased its holdings in shares of MKS by 2.3% during the third quarter. Wedmont Private Capital now owns 4,193 shares of the scientific and technical instruments company’s stock valued at $1,092,000 after acquiring an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of MKS by 13.5% during the third quarter. GAMMA Investing LLC now owns 3,667 shares of the scientific and technical instruments company’s stock valued at $973,000 after acquiring an additional 436 shares in the last quarter. 99.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades Several brokerages recently commented on MKSI. Deutsche Bank Aktiengesellschaft set a $360.00 price objective on shares of MKS in a research report on Friday, July 31st. Wall Street Zen raised shares of MKS from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Bank of America upped their target price on shares of MKS from $380.00 to $500.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Needham & Company LLC increased their price target on shares of MKS from $360.00 to $390.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Citigroup increased their price target on shares of MKS from $425.00 to $430.00 and gave the company a “buy” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $375.93.

Get Our Latest Report on MKS MKS Trading Down 6.0% MKSI opened at $214.83 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.72 and a debt-to-equity ratio of 0.85. MKS Inc. has a 12 month low of $130.72 and a 12 month high of $447.62. The firm has a market cap of $14.53 billion, a P/E ratio of 34.26, a P/E/G ratio of 0.48 and a beta of 2.03. The stock has a 50-day moving average of $265.44 and a 200 day moving average of $299.66.

MKS (NASDAQ:MKSI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The scientific and technical instruments company reported $3.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.91 by $0.39. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $1.20 billion. MKS had a return on equity of 24.72% and a net margin of 10.15%. MKS’s revenue was up 28.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.77 EPS. MKS has set its Q3 2026 guidance at 3.270-3.890 EPS. As a group, research analysts forecast that MKS Inc. will post 13.13 EPS for the current year.

MKS Announces Dividend The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Tuesday, August 25th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 25th. MKS’s dividend payout ratio (DPR) is 15.95%.

Insider Buying and Selling at MKS In related news, Director Elizabeth Mora sold 300 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $250.96, for a total transaction of $75,288.00. Following the transaction, the director directly owned 18,845 shares in the company, valued at $4,729,341.20. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Williams sold 457 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $288.31, for a total value of $131,757.67. Following the sale, the executive vice president owned 4,098 shares in the company, valued at $1,181,494.38. The trade was a 10.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 10,757 shares of company stock valued at $3,227,146. 0.57% of the stock is currently owned by insiders.

MKS Company Profile (Free Report)

MKS Instruments, Inc develops technologies used to measure, control and analyze the processes involved in manufacturing semiconductors, electronics, specialty materials and other industrial products. The company serves original equipment manufacturers and production facilities worldwide, with solutions spanning vacuum control, pressure measurement, gas and fluid delivery, process monitoring and control.

Its product portfolio includes vacuum gauges and valves, mass flow controllers, gas and vapor delivery systems, pressure controllers, plasma-generation and power-delivery systems, analytical instruments, lasers and photonics equipment.

Featured Articles Five stocks we like better than MKS Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding MKSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MKS Inc. (NASDAQ:MKSI – Free Report).

Receive News & Ratings for MKS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MKS and related companies with MarketBeat.com's FREE daily email newsletter.

Not all high-yield dividend stocks are created equal. Some are genuine income compounders, while others are traps. And the current environment, with interest rates on the rise, makes it more difficult to differentiate the good from the bad.

AbbVie (ABBV +0.71%) is by no means a high-yield trap. This pharma stock is well-positioned to succeed in any rate cycle.

Image source: Getty Images.

The exact opposite of a high-yield trap What makes a stock a high-yield trap? Different investors can have different criteria, but there's one tell-tale sign. A stock with a high dividend yield but a payout ratio consistently above its free cash flow is almost always a trap. If a company doesn't generate sufficient free cash flow, it will be forced to cut its dividend sooner or later.

Rising interest rates make it especially difficult for companies with balance sheets loaded to the gills with floating-rate debt. They frequently must shift funds from the dividend program to cover their higher interest expenses.

Similarly, a company with a business model whose revenue is highly sensitive to consumer spending can experience problems when rates increase. When consumers have to spend more of their money on car and home loans and credit card debt, they have less money to buy these companies' products.

AbbVie doesn't have issues on any of these fronts. The drugmaker generates more than enough free cash flow to cover its quarterly dividend payment of $1.73 per share. While AbbVie's debt totals $70.8 billion, much of it is in fixed-rate senior notes that aren't sensitive to interest rate fluctuations. Patients don't quit taking AbbVie's medications because interest rates go up, either.

ABBV AbbVie$285.42+$2.02 (+0.71%)

NYSE · As of 4:00 PM ET 10/16/26

The numbers add up for AbbVie Importantly, AbbVie has increased its dividend for 54 consecutive years (including the period when it was part of Abbott Laboratories (ABT +0.20%)). This achievement qualifies the company to be part of the Dividend Kings, a group of stocks that have increased their dividends for at least 50 consecutive years.

As you might imagine, Dividend Kings are loath to break their dividend-hike streaks and lose their status in the elite group. Both Abbott and AbbVie have ensured their dividends keep flowing and growing regardless of what the Federal Reserve does with rates.

AbbVie shouldn't have much trouble holding onto its Dividend King membership for two key reasons: Skyrizi and Rinvoq. These two autoimmune disease drugs together raked in over $7.5 billion in the second quarter of 2026 alone. That's more than the $6.1 billion the company paid in dividends during the quarter.

Another important number to know is 90. That's roughly how many programs the company has in clinical development. Around 60 of them are in mid- or late-stage clinical studies. This robust pipeline should help ensure that AbbVie continues to generate plenty of revenue in the future to grow its dividend.

A Dividend King to own for the long run To be sure, AbbVie's dividend yield of 2.5% isn't nearly as high as it's been in the past. However, that isn't a poor reflection on the company's ability to pay dividends. Instead, it's a testament to how great AbbVie's stock has performed in recent years. Its share price has risen so much that the solid dividend growth hasn't kept pace, causing this yield to slide.

Like all biotech and pharmaceutical companies, AbbVie faces the risk of pipeline setbacks. The good news, though, is that the company has enough therapies in development to remain successful even if some don't fulfill their potential.

In a market where investors can easily get stuck with high-yield traps, AbbVie offers a solution. It's an ideal Dividend King to own for the long run.

Shares of ad tech company The Trade Desk (TTD -6.86%) trade near $12 as I write, down about 91% from their December 2024 record closing price of $139.51. And shares have kept sliding this year, down about 68% since the end of 2025.

The company's now worth about $5.8 billion, and the stock costs about 14 times its earnings for the last 12 months. For a business whose revenue rose 18% year over year in 2025, that looks cheap. But management now expects revenue to shrink.

Where could the stock realistically be in a bit over three years?

My estimate is around $16 a share by the end of 2029, about 31% above today's price, or a gain of about 9% a year. I think it's a fair middle case. But it hinges on something the company hasn't forecast yet: a return to growth.

Image source: Getty Images.

Shrinking sales, fewer sharesThe Trade Desk is a tech company that runs a demand-side platform (software advertisers use to buy digital ads automatically), and as recently as last year the business looked healthy. Full-year 2025 revenue hit around $2.9 billion, and net income climbed about 13% to $443 million -- a net margin of about 15%.

Growth has since slowed sharply. Second-quarter 2026 revenue rose just 3% year over year to $715 million. Net income dropped around 29% to $64 million, cutting the net margin to 9% from 13% in the year-ago quarter. And management's guidance calls for third-quarter revenue of at least $650 million, which would be a decline of about 12% from the same period in 2025.

Still, one number keeps moving in shareholders' favor. Mainly because of buybacks, the company's diluted share count dropped from around 507 million in late 2024 to 483 million a year later, then to 470 million by this year's second quarter. The Trade Desk repurchased about 10 million shares for about $233 million in the first half of 2026 alone, and it still had about $1.5 billion in cash and short-term investments and no debt at the end of June.

So per-share earnings can arguably rise faster than profits, even if the business recovers slowly.

What would it take to hit $16?Say revenue rebounds to 2025's level of about $2.9 billion by 2027 and then rises about 6% a year. This gets The Trade Desk to about $3.3 billion of revenue in 2029, growth at about a third of the rate it managed in 2025.

If the net margin also returns to the 15% the business had in 2025, net income could be near $490 million in 2029.

Assume buybacks cut the diluted share count to about 450 million, a slower rate of decline than the past 18 months. That works out to about $1.09 of earnings per share.

At 15 times earnings (near the price-to-earnings ratio the stock trades at now), shares would be worth around $16.

Notably, I'm not assuming a higher valuation multiple, just that the company stops shrinking and earns its 2025 net margin again.

$12.23-$0.90 (-6.86%)

NASDAQ · As of 4:00 PM ET 10/16/26

A lot could go wrongThe biggest risk is that revenue doesn't rebound on that schedule. If sales settle around $2.8 billion and the net margin stalls at about 10%, earnings per share could be about $0.61 on 460 million shares. At 12 times earnings, the stock would be worth around $7, or about 40% below its current price.

The share count assumption has its own risk. On Monday, Oct. 19, shareholders vote on a proposal to reprice stock options for up to around 15.6 million shares, or about 3% of the outstanding shares. Exercise prices for these options go up to $122.59, and if the proposal passes, any above that day's closing price would be cut to the close. Options priced near the stock might increase dilution if shares recover, which is the scenario my forecast assumes.

In the end, a gain of around 9% a year would be a decent result from here. But it hinges on a recovery The Trade Desk hasn't guided to, and my bear case drops more than my base case climbs. This prediction doesn't change the take I spelled out last month, when I explained why I'm still not buying the stock.

Until management's revenue forecast points up again, I'd rather not pay even 14 times earnings for the shares. Sure, three years is a long time, and my estimate could miss in either direction.

The Euro-Dollar Edges Higher Near $1.124 as Nordea Cuts Its Recovery Outlook
Nordea analysts forecast the Euro to weaken against the US Dollar as French fiscal risks and US investment flows outweigh the currency's latest recovery.
The Euro-to-Dollar exchange rate edged higher on Friday, trading at $1.1237 ahead of the weekly close, although EURUSD remained about 2% lower over the past month.

Latest-Exchange Rates:

Euro to Dollar (EUR/USD): 1.12394 (+0.23%)

Pound to Dollar (GBP/USD): 1.33301 (+0.44%)

Dollar to Yen (USD/JPY): 157.99261 (-0.09%)

FX analysts at Nordea expect that recovery to falter, having cut its end-2026 EUR/USD forecast to 1.10 from 1.14 after the exchange rate reached its previous first-half 2027 objective sooner than anticipated.

The bank now sees a test of 1.08 in the first half of next year.

Nordea argues that France's financing difficulties and continued demand for American technology investments leave Europe at a disadvantage even after the Euro's recent losses.

That is a more cautious December view than the latest projections from UBS and Crédit Agricole, which put EUR/USD at 1.16 and 1.13 respectively for end-2026.

France's higher yields carry a different message
Higher bond yields can attract currency demand when they reflect stronger growth and better prospective returns.

Nordea sees a less reassuring explanation for the extra yield investors require to hold French government bonds rather than German Bunds.

The bank writes: "The sharp widening in OAT-Bund spreads therefore appears to reflect more than a routine bout of risk aversion around the French budget. Markets are assigning a broader premium to France's fiscal and political outlook, reinforcing downside risks to the euro."

France's challenge is to convince investors that its borrowing needs can be contained while it negotiates a credible 2027 budget ahead of next year's presidential election.

With debt-servicing costs increasing, further monetary tightening could make that task harder even if it helps restrain inflation.

Nordea identifies a problem extending beyond France: "The pressure is greatest in highly indebted economies, where weak growth and limited appetite for reform leave public finances increasingly exposed to higher global yields."

It adds: "Unlike the US, these economies lack the nominal growth needed to offset rising borrowing costs, further constraining fiscal space as interest expenses climb."

Exchange Rates UK's coverage of France's increasingly country-specific borrowing premium also examined why a rise in French yields need not strengthen the Euro.

Money switching into other Euro-denominated assets would have a different currency effect from investors reducing their exposure to the region altogether.

Inflation does not give Europe the same rate advantage
Friday's final Eurostat inflation release confirmed annual price growth of 3.8% in September, with energy making the largest contribution.

That keeps pressure on the European Central Bank, but Nordea expects expensive energy to favour the US relative to Europe through its effect on trade and economic activity.

A larger import bill can squeeze European household and business spending while supporting income in an energy-producing economy.

Nordea's policy assessment is explicit: "Our baseline remains a strong US economy and two further Fed hikes, with risks skewed to the upside. By contrast, the balance of risks around the ECB's hawkish stance has shifted to the downside, keeping the short-end rate differential in the dollar's favor."

The difference in expected short-term rates influences the relative return available on Dollar and Euro assets.

Subsequent US activity figures give that argument some support without settling the policy outlook.

The Federal Reserve's September industrial-production report, released on Friday, showed output rising 0.7% on the month, although a large utilities increase helped drive the headline gain.

Manufacturing rose a more modest 0.3%, so the report offers evidence of continued expansion rather than an equally strong acceleration across industry.

The Dollar call depends on investment holding up
A rate advantage is only part of Nordea's explanation for persistent Dollar demand.

"Inflows into US equities and credit are unlikely to fade simply because interest rates are slightly higher."

"Passive investment reinforces this trend because broad indices remain heavily concentrated in US mega-cap technology stocks. To the extent that these flows remain unhedged, they create sustained demand for dollars."

Overseas investors can protect themselves against exchange-rate movements, reducing the net currency exposure associated with buying American assets.

The possible stabilisation discussed in our earlier coverage of Scotiabank's oversold-Euro assessment concerns a shorter horizon than Nordea's fundamental call.

A rebound need not require an immediate reversal in the investment flows supporting the Dollar.

For now, Nordea finds little evidence that the cycle is turning: "South Korean and Taiwanese exports are improving, as are global PMIs, while earnings have remained solid and repeatedly exceeded analysts' expectations in recent quarters. These indicators do not rule out high valuations, but they provide little evidence that the investment cycle is already turning."

Nordea does expect conditions to become more favourable for the Euro later in 2027 as US inflation eases and Fed tightening ends.

An earlier disruption to technology investment could bring that reassessment forward: "The main risk to our EUR/USD forecast is a sharp reversal in the AI investment cycle. A bursting AI "bubble" would weaken US asset inflows and challenge our dollar-positive view."

Euro to Dollar exchange rate FAQ
What is Nordea's EUR/USD forecast?

Nordea has cut its end-2026 projection to 1.10 and expects a test of 1.08 in the first half of 2027.

Why does Nordea expect further Euro weakness?

It points to US rate support, European fiscal and energy pressures, and continued investment flows into American assets.

What could challenge that forecast?

An abrupt reversal in AI investment could weaken US capital inflows and undermine Nordea's positive Dollar view.

Walt Disney's (DIS -0.08%) place is in the living room. Its popular cable channels helped it establish a dominant position in the media and entertainment industry. But this part of the business faces secular decline, as U.S. households have been cutting the cord. The linear networks aren't as lucrative as they once were.

The company has transitioned successfully this decade in the streaming age. It's been a costly evolution, though. But Disney+, Hulu, and the direct-to-consumer (DTC) ESPN platform give Disney a comprehensive content offering that caters to everyone in the family.

While changes have happened on the TV screen, the experiences segment continues to drive the lion's share of financial results. And the business is investing aggressively here.

Shareholders have witnessed multiple CEO changes, from Bob Chapek to Bob Iger to Josh D'Amaro. And the consumer discretionary stock has disappointed amid all of this turbulence. It currently trades 46% off its peak (as of Oct. 14). And it's down 4% in 2026, lagging the broader market.

There's one stat, however, that makes the House of Mouse hard to ignore in October.

Image source: The Motley Fool.

The valuation represents a discount to the market Disney shares trade at a forward price-to-earnings ratio of 13.8 right now. That's significantly cheaper than the S&P 500's 19.6 multiple. It looks like a compelling bargain opportunity. That point carries extra weight when the market is near record territory. And given that it's been four years since this raging bull market started, investors might find it challenging to identify reasonably valued stocks.

As noted earlier, Disney hasn't been running a simple and easy-to-follow business. It seems that there are a lot of moving parts. And the market could be punishing the stock because of it.

The legacy cable networks continue to be a financial drag. From fiscal 2022 to fiscal 2025 (last available data), operating income fell 65%. That's not surprising because, according to eMarketer, the number of cable-TV households in the U.S. will decline again in 2026 to 54 million. That's down from 105 million households in 2010. Consumers have increasingly moved their attention to streaming entertainment, which has hurt legacy media players.

And this is a capital-intensive business. In addition to expanding its experiences division, Disney must constantly invest in content that seems to get more expensive every year. This is particularly true with valuable sports rights. Big tech enterprises have entered the arena, which can result in costly bidding wars.

Competition for eyeballs is also intense these days. And it's a crowded race to capture consumer discretionary spending. Moreover, the investment community might simply be chasing what has been the hottest trade, which is owning artificial intelligence stocks.

$110.59-$0.09 (-0.08%)

NYSE · As of 4:00 PM ET 10/16/26

Take a five-year view Knowing the negative factors, I still believe the valuation makes Disney shares too hard to ignore this month. For less than 14 times forward earnings, investors can own a stake in a high-quality company.

It all starts with something that no rival can copy, which is Disney's intellectual property (IP). Decades of characters, franchises, and stories can't be rebuilt with any amount of capital. This supports the company's economic moat.

The entertainment DTC operations, including Disney+ and Hulu (excluding live TV), have turned the corner on profitability. Operating income soared more than 100% year over year in Q3 (ended June 27) to $712 million. In fiscal 2022, it posted a sizable operating loss of $4 billion (including ESPN+). This is an emerging bottom-line tailwind.

Then there's the experience segment. The main drivers here are the theme parks and cruises, both of which are expanding as part of a 10-year, $60 billion capital expenditure cycle announced three years ago. The segment's Q3 operating income of $3 billion, accounting for 54% of the company's total, demonstrates how lucrative it is for Disney to bring its IP to life.

Patient investors with a five-year horizon have plenty to like here.

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs
Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis
New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.

"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical," said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie. "The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD."

Key data to be presented include:

Long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) – Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib

Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remissiona rates of 54.0%–73.1% and endoscopic remissionb rates of 38.8%–53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients.
Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remissionc was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remissiond was achieved by 47.1% and 64.2% of patients, respectively.

Upadacitinib in the Real World: New Insights from Clinical Practice

Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical responsee with upadacitinib within 12 weeks, with a median time to first response of 13 days.
A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.

Additional Findings on Risankizumab Subcutaneous Induction in CD

Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment.

aDefined as stool frequency (SF) score ≤ 1, and not greater than baseline, rectal bleeding score = 0, and endoscopic subscore ≤ 1 without evidence of friability.
bDefined as endoscopic subscore = 0.
cDefined as average daily very soft or liquid SF ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than induction baseline.
dDefined as Simplified Endoscopic Score for Patients with Crohn's Disease ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer.
eDefined as the first day with ≥30% decrease in daily very soft or liquid SF and/or ≥30% decrease in daily AP score and both not worse than baseline AND a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO was defined as ≥30% decrease in average daily very soft or liquid SF and/or ≥30% decrease in average daily AP score and both not worse than baseline. Only patients with either baseline SF or AP >0 and both non-missing with at least one postbaseline assessment of CR-PRO2 are included.

The 2026 UEGW Congress program is available here. Select abstracts and oral presentations from AbbVie include:

Presentation Title

Session Details

Efficacy of Risankizumab by Crohn's Disease
Location: Results From 144 Weeks of the
FORTIFY Open-Label Extension Study

Oral

Monday, 19 October

16:00 – 17:00

OP165: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Risankizumab
Subcutaneous Induction in Patients With
Moderately to Severely Active Crohn's Disease:
Week 12 Results From the Phase 3 AFFIRM Study

Oral

Monday, 19 October

16:00 – 17:00

OP166: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Subcutaneous
Risankizumab Maintenance Therapy Among
Patients With Moderately to Severely Active
Crohn's Disease Who Responded to
Subcutaneous Risankizumab Induction Therapy:
24-Week Results From the AFFIRM Trial

Moderated poster

Monday, 19 October

16:00 – 17:00

MP0087: The IBD exposome: Diet,
environment, and sustainability

Sustained Clinical and Endoscopic Improvements With
up to 3 Years of Risankizumab Maintenance
Treatment in Patients with Moderate to Severe
Ulcerative Colitis Regardless of the Number of Prior
Advanced Therapy Exposures

E-Poster

17-20 October

PP1176

Efficacy and Safety of Upadacitinib Maintenance
Therapy in Moderately to Severely Active
Crohn's Disease: 144-Week Results From the U-
ENDURE Long-Term Extension Study

Oral

Monday, 19 October

11:30 – 12:30

OP108: Long term outcomes
of interventional trials in IBD

Effectiveness of Upadacitinib Treatment in
Moderate to Severe Crohn's Disease in Real-
World Clinical Practice: 6-Month Results From
the UPlift Study

Moderated poster

Sunday, 18 October

09:00 – 10:00

MP0015: Therapeutics in IBD - Real
world experience (3)

Comparative Health Care Resource Use and
Treatment Patterns Following Tumor Necrosis
Factor Inhibitor Cycling Versus Switching to
Upadacitinib: A Propensity Score Matched
Analysis

Oral

Tuesday, 20 October

14:30 – 15:30

OP292: Real world observations in IBD:
Things we don't see in clinical trials

ABBV-466, A Novel Dual-targeting Therapy,
Leads to Endoscopic Remission in Moderate-to-
severe Crohn's Disease: Primary Results and

Molecular Profiling from the Phase 2a TARGET-
CD study

Oral

Monday, 19 October

10:00 – 11:00

LB08: Late-Breaking IBD Trials 

SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. 

About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.1 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of moderately to severely active plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.1,2

On August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency (EMA) seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

EU Indications and Important Safety Information about SKYRIZI® (risankizumab)1 

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.3,4 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.3

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)3

Indications

Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSpA) 
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy).

Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.

Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.

Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.

Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.

Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.

Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.

Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.

The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.

The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.

The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.

The most common serious adverse reactions were serious infections.

The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.

RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About TARGET-CD:
TARGET-CD (M24-885) is a global Phase 2a, multicenter, randomized platform study designed to evaluate multiple investigational targeted therapies, including monotherapy and combination approaches, in adults with moderately to severely active Crohn's disease. The innovative platform design enables evaluation of the efficacy, safety, and mechanistic profiles of different therapeutic strategies using a common comparator, with the goal of rapidly advancing new treatment approaches for patients with Crohn's disease. More information on the TARGET-CD trial can be found at www.clinicaltrials.gov (NCT06548542).

About ABBV-466:
ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. The approach is designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut, with the goal of achieving deeper disease control than either pathway alone.

ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SKYRIZI. Summary of product characteristics. AbbVie; 2026.
SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
RINVOQ. Summary of product characteristics. AbbVie; 2026.
Pipeline. AbbVie. 2026. Accessed September 24, 2026. https://www.abbvie.com/our-science/pipeline.html

SOURCE AbbVie

3 hours ago

Fidelity Digital Assets recently released an analysis noting that the 10-year U.S. Treasury yield has risen to its highest level since Bitcoin’s inception, while the size of U.S. federal debt has surpassed $40 trillion, with interest payments exceeding Medicare to become the second-largest expenditure item in the federal budget. Fidelity pointed out that Bitcoin’s correlation with the 10-year U.S. real interest rate was long low, but has gradually turned positive in recent years, rising above 0.6 in 2026, a record high. Over the past two months, Bitcoin has rallied nearly 30%, while the 10-year U.S. Treasury yield has jumped more than 10% in the same period. Fidelity argues that amid rising government debt, higher financing costs and growing concerns over fiscal intervention, Bitcoin’s fixed supply cap of 21 million coins may boost its appeal as a potential hedge against currency devaluation and a portfolio diversification tool. If current debt and interest rate trends persist, government interest payments could even become the largest expenditure item in the federal budget in the future. U.S. Treasury data shows that the U.S. federal budget deficit for fiscal 2026 rose to $1.99 trillion, up from $1.78 trillion in fiscal 2025, the highest level since the COVID-19 pandemic. Despite the Trump administration’s pledge to cut spending, military spending, Social Security expenditures and Treasury interest payments continue to climb, coupled with a decline in corporate tax revenue, further expanding the fiscal deficit.

Scan the QR code

Download APP

Ripple CEO Brad Garlinghouse has explained why the company contributed a significant amount of XRP to Evernorth, the XRP treasury company that recently debuted on Nasdaq. Speaking at Nasdaq on the company’s listing day, he said the move fits Ripple’s long-standing approach of investing in its own ecosystem, and that his trust in Evernorth’s leadership sealed the decision.

Why Ripple backed Evernorth

Asked why Ripple put its tokens into Evernorth, Garlinghouse said supporting the community has been part of Ripple’s strategy “since really its inception.” That support has sometimes reached beyond XRP, he added, because Ripple believes in “a multi-chain world.”

The deciding factor was Evernorth CEO Asheesh Birla, who previously worked under Garlinghouse at Ripple and later sat on its board. “When Asheesh raised his hand and expressed interest, that to me cemented our interests,” Garlinghouse said.

He described Birla as “an extraordinary leader” who has shown “unique acumen around talent, around strategy,” both at Ripple and now at Evernorth.

How it helps XRP

Garlinghouse said Evernorth’s listing strengthens the XRP ecosystem in three ways:

Liquidity and trust: The listing “furthers liquidity” and “trust in the XRP ecosystem,” he said.New investors: A listed company opens XRP to people who cannot easily access crypto markets directly. “Just that is a major step,” he said.More than buy-and-hold: Evernorth plans to use on-chain and off-chain strategies to earn yield and build institutional products, which he said “positions XRP to perform really well.”He also explained how hard it has been to reach this point. “There were a couple hundred various DATs trying to get public,” he said, referring to digital asset treasury companies. “The fact that we are here today with XRP trading is a big deal.”

“Ripple was on to something”

Garlinghouse reflected on Ripple’s years as an outsider in crypto. Many early crypto users held a strongly anti-establishment view, and Ripple drew criticism for building for banks and traditional finance.

“For a bunch of years, Ripple was a controversial contrarian because we were leaning into TradFi as our core customer set,” he said. Now the market has come around, and “a lot of other players in the industry recognise that hey, maybe Ripple was on to something there.”

The hard years are not over

Garlinghouse stopped short of declaring victory. “I’m not ready to say the hard years are behind us,” he said.

Still, he believes markets are underestimating the shift in the US. The United States accounts for about 22% of global GDP and spent years “leaning out” on crypto, he said. Now its institutions are “leaning in like they never have before.”

Story Ends Here

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Read the Next News

Cardano’s (ADA) price has come under pressure, declining 2.3% in the last 24 hours to $0.2248, despite a substantial rise in the network’s stablecoin market capitalization. Data from Cardanians (CRDN) shows that Cardano’s stablecoin market cap has expanded by 25.8% over the past 90 days, climbing to $68.3 million.

Stablecoin growth and top contributorsThis jump in stablecoin capitalization highlights growing activity in Cardano’s ecosystem, as dollar-pegged assets play a larger role in decentralized finance (DeFi) trading and application usage. According to Cardanians, USDC currently leads with $44.4 million, followed by USDM at $13.5 million and RealFi’s USDrf at $5.1 million.

Stablecoin market cap on Cardano $ADA has grown by 25.8% in the past 90 days. Currently it’s at $68.3M, led by USDC with $44.4M. RealFi’s USDrf launched just recently and has already reached $5.1M. Great to see the growth, hoping to see $100M+ soon!

The increase in stablecoin balances signals that users are increasingly utilizing Cardano for transactions, DeFi applications, and transfers, without frequently moving assets into traditional currencies.

Mini dictionary: Cardanians is a Cardano-focused analytics and advocacy community that tracks on-chain data, network metrics, and ecosystem trends. They share insights on ADA’s performance and growth, often through social media channels such as X.

ADA price under pressure, key technical levels in focusDespite the stablecoin uptrend, ADA’s price remains subdued. Technical charts from TradingView reveal that ADA fell back after touching $0.28 in early October, sliding below resistance at $0.2432. Traders now focus on the crucial support level near $0.2053, which could determine whether the token stabilizes or faces further downside.

A move above $0.2432 would see ADA return to its recent trading range, though bulls must sustain buying pressure to advance a recovery. Until then, ADA continues to trade below resistance, keeping sentiment uncertain.

StablecoinMarket Cap ($ million)USDC44.4USDM13.5USDrf5.1Total68.3If ADA maintains support above $0.2053, it could allow time for consolidation. A breakdown below this zone, however, would increase risk of further declines.

Technical indicators and market signalsCardano’s Relative Strength Index (RSI) is currently at 42.82, below its moving average of 53.70, suggesting weakening bullish momentum. The RSI remains above the oversold threshold of 30, meaning the market yet waits for a clear oversold signal.

The On-Balance Volume (OBV) indicator has dropped to approximately 45.25 billion, consistent with declining buying interest. Although both indicators suggest softer demand, traders look for signals such as the RSI rising above 50 or an uptick in OBV before confirming a turnaround.

Open interest and DeFi metricsCoinGlass data reveals that ADA futures open interest has decreased from around $650 million in early October to about $500 million now. Liquidations have been observed on both long and short positions during recent volatility, indicating that leveraged traders face pressure in both directions.

Decreasing open interest may reflect reduced speculative positions, but does not in itself confirm whether investors are favoring bullish or bearish bets. Monitoring stabilization in open interest, along with price momentum and support levels, could provide clearer insight for traders.

Separately, DeFiLlama shows Cardano’s total value locked (TVL) has reached $65.21 million, while decentralized exchange (DEX) volume stands at $1.45 million for the past day. These figures highlight ongoing activity in Cardano’s DeFi ecosystem as stablecoin balances grow.

While higher stablecoin capitalization indicates expansion, it does not guarantee an increase in DeFi participation or demand for ADA itself. Traders continue to watch for a link between rising on-chain volumes, ecosystem usage, and a shift in price momentum.

In the near term, ADA’s outlook hinges on whether positive network indicators join with technical recovery moves—such as recapturing the $0.2432 resistance and improving RSI and OBV readings. Conversely, losing the $0.2053 support could place the token at greater risk of further losses even amid ecosystem advances.

On its third quarter of 2026 earnings call, held on Oct. 14, 2026, BlackRock (BLK +1.21%) announced quarterly net inflows of $205 billion. This capital influx pushes assets under management, the total market value of investments the firm manages for clients, to $15.5 trillion. Expanding beyond traditional index funds into private credit and infrastructure creates durable recurring fees across changing market environments. Three takeaways from the call highlight how this strategy powers long-term growth.

1. Private Markets Expand Into Artificial Intelligence InfrastructureManagement is positioning the firm at the intersection of private credit and technology infrastructure by financing massive data center builds. Integrating Global Infrastructure Partners (GIP), an infrastructure investment manager, and HPS Investment Partners, a private credit firm, gives the company full capability across corporate debt and equity structures.

We partnered with Meta on the financing of its planned $14 billion data center in Texas, bringing together infrastructure investments from GIP, private financing capabilities from HPS.
-- Laurence D. Fink, Chairman and Chief Executive Officer2. Organic Base Fee Growth Accelerates Across Asset ClassesOrganic base fee growth, which measures recurring fee revenue earned from client net inflows excluding market moves, reached 11% in the quarter. Scaling higher-fee categories like private markets and technology services keeps revenue growing even when underlying equity markets fluctuate.

Third quarter organic base fee growth was 11%. That's nine consecutive quarters at or above our 5% long-term target, and it's also the fifth consecutive quarter at or above 8%.
-- Martin S. Small, Chief Financial Officer3. Active Exchange-Traded Funds Drive Record InflowsInvestors are increasingly using exchange-traded funds, or pooled investment funds traded on public exchanges, for active management rather than simple market tracking. Expanding active offerings into exchange-traded fund structures lets the firm gather higher-margin fees while consolidating market share from traditional mutual funds.

The ETF wrapper is also evolving how investors access actively managed strategies, and iShares is leading the industry with $60 billion of active inflows in 2026, including a record $22 billion of inflows this quarter.
-- Laurence D. Fink, Chairman and Chief Executive OfficerLooking AheadCapital flows into private infrastructure and specialized fixed income are accelerating, and management isn't hiding its satisfaction about the momentum. Deep relationships with technology companies and institutional investors give the platform a distinct edge in structuring complex financing deals.

Management is watching the buildout of artificial intelligence compute financing, expanding Aladdin, the firm's investment and risk management technology platform, and maintaining pricing discipline across customized wealth portfolios.

More clients are turning to BlackRock as a destination for capital and for a partner for their growth.
-- Laurence D. Fink, Chairman and Chief Executive OfficerAs traditional banking channels face capital constraints, institutional clients are turning to private markets and technology-driven portfolio management. The firm's ability to unify public markets, private credit, and enterprise software positions it to capture long-term market share.

I am confident in the opportunities and growth ahead for BlackRock, for our clients and importantly, for our shareholders.
-- Laurence D. Fink, Chairman and Chief Executive Officer

Hedera (HBAR) reports higher TVL and TPS over 30 days, joins the UK Wholesale Digital Markets Champion Taskforce and opens its CLPR cross-ledger protocol to developers.

Hedera (@hedera) has recorded gains in network activity alongside a run of institutional and developer milestones. Total value locked (TVL) on the network reached $33.2 million, up 12.3% over 30 days, while transactions per second (TPS) rose 168.37% over the same period, based on recent Token Relations data.

Institutional steps for Hedera and $HBARHedera has become part of the UK's Wholesale Digital Markets Champion Taskforce. The taskforce is led by Christopher Woolard CBE and supported by HM Treasury, and focuses on interoperability and settlement finality in tokenized repos , according to Coinfomania. Other priorities include tokenized fixed income and collateral, with interoperability across public, private and existing financial infrastructure a key theme.

The move fed into a broader institutional narrative around the token. AMBCrypto noted that news of the taskforce seat came as Hedera was strengthening the institutional adoption narrative during a sharp rally in $HBAR in late September.

CLPR goes open sourceOn the technical side, Hedera has made its CLPR cross-ledger protocol open source through Linux Foundation Decentralized Trust (LFDT) Labs. According to Hedera, CLPR (pronounced "clipper") is the bridgeless Cross-Ledger Protocol in development by Hashgraph, contributed to LFDT as a new lab on 24 September.

The design aims to remove the need for bridges. CLPR uses state proofs to allow ledgers to verify each other's states directly, with no intermediaries in between. That matters because bridges and wrapped assets have been a weak point for the sector. Genfinity, citing industry trackers, reported that bridge incidents have cost roughly $329 million across eight attacks this year .

Alongside the contribution, Hashgraph opened a three-phase Cross-Ledger Early Adopter Program focused on cross-border payments and in-flight FX, cross-ledger settlement, and collateral mobility. The code now sits in LFDT's repositories, where developers can review it and contribute before it reaches top-level project status.

Application layer and developer toolingIn the application category, HashPack and SODAX are working to widen access to tokenized assets. Additional SDK functionality and updated atomic batch rules were also among the recent developer-side updates.

Taken together, the data points to rising on-chain activity, a clearer institutional footprint in the UK and an open-source push on interoperability. TVL of $33.2 million remains modest in absolute terms, so the next test will be whether these initiatives translate into sustained usage.

Sources:

Hedera: Hedera Contributes Hashgraph-Developed CLPR to LFDT LabsCoinfomania: Hedera Joins UK's Wholesale Digital Markets TaskforceGenfinity: Hedera Contributes Bridgeless CLPR Protocol to LFDT

Changpeng Zhao wants one thing on the record: he did not get Solana’s Shanghai ad pulled.

The Binance founder said on X that the advertisement on the city’s Bund came down within 10 minutes of appearing. He says that happened before he had even seen it. His post praising Solana followed later.

A celebration, then a crackdown
On October 15, 2026, CZ publicly applauded Solana’s new Shanghai office and its skyline advertising in the city. He framed the move as a meaningful step forward for the blockchain industry as a whole. He also set it against what BNB Chain had accomplished, a notable gesture of goodwill toward a rival ecosystem.

On October 16, 2026, Solana’s Accelerate China event at the Shangri-La hotel in Shanghai was postponed after police showed up. Attendees reported being kept outside the venue for more than an hour.

Organizers attributed the delay to “last-minute logistical considerations.” They did not elaborate on what, if anything, had passed between them and the authorities.

Speculation filled the gap. The theory making the rounds was simple: CZ’s high-profile praise had drawn the attention of regulators. In that telling, his post triggered scrutiny that led to the ad on the Bund being taken down just 10 minutes after it went up.

CZ’s version of the timeline
CZ rejected that account directly. His argument rests on sequencing.

By his account, the ad was already gone within 10 minutes of being displayed. He says he did not see it until much later. According to the research timeline, his social media post came 12 to 24 hours after the ad was removed.

CZ also pointed to China’s strict real-time content monitoring. His point was that the ad’s rapid removal fits a system built to catch this kind of material quickly, with or without a nudge from a celebrity founder on X.

China’s long, complicated relationship with crypto
China has kept its ban on crypto trading in place since 2021. At the same time, the country continues to allow blockchain development.

This is also not Solana’s first rough experience in mainland China. The postponement marked the second time in a year that a Solana event in the country was disrupted. The earlier incident took place in Shenzhen in 2025.

What this means for Solana and foreign crypto projects
For Solana, the immediate cost is reputational and logistical. A postponed flagship event and a vanished billboard are not the launch most teams envision for a new office.

CZ’s role here is interesting on its own terms. He offered public support to a competing chain, then had to spend time explaining that the support did not backfire.

The near-term reality is a canceled ad and a delayed conference.

What to watch next is fairly straightforward. Will Solana reschedule Accelerate China, and under what terms? Will organizers say more about what the authorities raised?

Disclosure: This article was edited by John Chen. For more information on how we create and review content, see our Editorial Policy.